- July 23, 2020 / BIOON / – – in a new study, researchers from the University of Illinois at Chicago have developed a new drug that prevents blood clots without increasing the risk of bleeding, a common side effect of all antiplatelet drugs.
- The new study describes the drug and its delivery mechanism, and points out that it is also an effective treatment for heart disease in animal models.
- Subsequently, the peptide derived nanoparticle drug, known as m3mp6 peptide loaded nanoparticles (hlpn), was tested in mice as a potential treatment for heart disease.
- reference material:
- Our 0 defect has passed the FDA certification, and has become the first-class professional polypeptide drug and product development and large-scale production and export industry in China .
July 23, 2020 / BIOON / – – in a new study, researchers from the University of Illinois at Chicago have developed a new drug that prevents blood clots without increasing the risk of bleeding, a common side effect of all antiplatelet drugs.
The results of the study were published in the Journal of Science Translational Medicine on July 15, 2020, with the title of “high loading g α 13 binding exe peptide nanoparticles prevent Thrombsis and protect mic from cardiac ischemia / reperfusion injury”. The corresponding author is Dr. Xiaoping Du, Professor of pharmacology and professor of regenerative medicine at the University of Illinois at Chicago.
The picture is from Science Translational Medicine, 2020, doi:10.1126/scitranslmed.aaz7287 。
The new study describes the drug and its delivery mechanism, and points out that it is also an effective treatment for heart disease in animal models.
“Unfortunately, current antiplatelet drugs can prevent the formation of blood clots that cause heart disease and stroke, but they can also damage the ability of platelets to stop bleeding if blood vessels break,” Du said. In some cases, severe bleeding can be life-threatening. What’s amazing about this new drug is that it prevents blood clots, but it doesn’t make people bleed easily, which other drugs can’t do
In a previous study, Du and his colleagues found that a signal transduction mechanism plays an important role in the formation of blood clots, but it is not necessary for platelets to adhere to wounds and stop bleeding. Based on this discovery, the researchers obtained a peptide targeting this signal transduction mechanism and designed a nanoparticles that successfully delivered the peptide to platelets.
Subsequently, the peptide derived nanoparticle drug, known as m3mp6 peptide loaded nanoparticles (hlpn), was tested in mice as a potential treatment for heart disease.
A heart attack can lead to heart failure and death in two different ways, Du said. One is from the initial damage caused by a blood clot, which blocks blood flow and reduces oxygen supply. This is usually treated by angioplasty and stenting to open the artery, combined with antiplatelet drugs to prevent it from forming clots again. However, when the arteries reopen, fresh blood flowing into the damaged heart tissue can cause inflammation, leading to small vessel leakage and clotting, which can further cause heart damage, Du said.
“This is called reperfusion injury, which is the second way a heart attack causes heart failure or death,” Du said. We hope that this new drug, which does not cause vascular leakage, will help limit reperfusion injury and reduce the risk of heart failure and death. Our hypothesis has been proved to be correct – we see very promising results from this study. “
In the new study, mice treated with the drug by injection had less heart damage, less blood clotting and less inflammation. In addition, their heart function has improved and their survival rate has improved.
“It’s very exciting to see such promising results in the laboratory, and we hope to be able to conduct clinical trials in humans one day,” Du said (Bio Valley) Bioon.com )
reference material:
1.Aiming Pang et al. High-loading Gα13-binding EXE peptide nanoparticles prevent thrombosis and protect mice from cardiac ischemia/reperfusion injury. Science Translational Medicine, 2020, doi:10.1126/scitranslmed.aaz7287.
2.New antiplatelet drug shows promise for treating heart attack
For sale, buy peptides, purchase peptides, and buy peptides online, you can find the Chinese peptide company:
Shengnuo Biotechnology is a high-tech China polypeptide manufacturers,who has over 19 years experience for the biotechnology .Our Products involve peptide raw materials,polypeptide drug.
Our 0 defect has passed the FDA certification, and has become the first-class professional polypeptide drug and product development and large-scale production and export industry in China .
Our service scope：peptide synthesis、peptide hormones、peptide medicine、beauty peptide、peptide medicine product、peptide technology transfer、peptide technology service、peptide large-scale production、export of peptide
Thymopentin for Injection、 Thymalfasin for Injection 、 Bivalirudin 、Bulk Drug、 Liraglutide ……
How many companies are there in peptide api manufacturer in china? The peptide api market is very promising, and the world is encouraging the development of peptide business. There is a peptide api list on the website Biofda.com, which contains various specifications of peptide APIs for customers to choose from. Shengnuo Technology is a peptide api manufacturer located in Chengdu, a city in southwest China. Not only peptide APIs, but also carnosine custom suppliers and cosmetic peptide suppliers
are many peptide apis manufacture in China, but they are all small-scale companies. The China peptide company such as Sinotech is a leading company in China and has a very high position.
As a Chinese peptide company, Sinotech has been working silently, hoping to become a top peptide company in the world. There are many countries producing peptides in the world, such as bulk drug substance in India, gmp custom peptide in uk, and peptide production in usa. So what is polypeptide? What kind of peptide synthesis supplier should you choose? Follow our website: www.biofda.com, here will tell you the answer.